Optimal management of human immunodeficiency virus type 1 (HIV-1)-infected children requires a commitment from the healthcare delivery system, healthcare providers, and affected families and caregivers. When adequate resources are available (as in most industrialised nations), an aggressive...

Background:Background: Male circumcision (MC) has become an important weapon in the fight against HIV/AIDS in many Sub-Saharan African countries. The successful implementation of a national MC program requires the design of circumcision services that are attractive to young men of various ages....

Background: While much is known about the association between drug regimen complexity and drug adherence, little is known about how this association is affected by patient depression. Objective: To examine whether the relationship between medication adherence and highly active antiretroviral...

With the advent of highly active antiretroviral therapy (HAART), HIV-infected patients are living longer and are concerned not only with a treatment's ability to extend their life but also with the quality of the life they are able to lead. Regulatory authorities are also paying closer attention...

Objective: To assess the temporal relationship between the uptake of more aggressive antiretroviral (ARV) therapy and the use and cost of hospital treatment for HIV-infected patients in France from 1995 to 2000 from a hospital perspective. Methods: Analysis of evolutions in health status (CD4+...

Background: Highly active antiretroviral therapy (HAART) has greatly enhanced HIV management, lowering the risk of clinical disease progression and death by substantially improving HIV-induced immune deficiency. Lower CD4 cell counts have consistently been associated with higher direct costs of...

Background: Given the association between CD4 cell counts and HIV-related morbidity/mortality, new antiretroviral therapies could potentially lower the direct costs of HIV care by raising CD4 cell counts. Objectives: To predict the effects of the ritonavir-boosted, HIV protease inhibitor (PI)...

The global prevalence of HIV infection continues to grow, as a result of increasing incidence in some countries and improved survival where highly active antiretroviral therapy (HAART) is available. Growing healthcare expenditure and shifts in the types of medical resources used have created a...

Background: Very few studies have evaluated the cost of highly active antiretroviral therapy (HAART) per successful treatment in HIV-infected patients. Objectives: To evaluate the cost of achieving undetectable plasma HIV-RNA levels in highly treatment-experienced, HIV-1-infected adults...

In this article we analyse how the costs of treating patients with HIV infection in the US have changed over time, with an emphasis on the relationship between inpatient hospitalization costs and the costs of highly active antiretroviral therapy (HAART). We examine how HIV treatment modes have...